Authors
Motzer, RHutson, T
Cella, D
Reeves, J
Hawkins, Robert E
Guo, J
Nathan, P
Staehler, M
de Souza, P
Merchan, J
Boleti, E
Fife, K
Jin, J
Jones, R
Uemura, H
De Giorgi, U
Harmenberg, U
Wang, J
Sternberg, C
Deen, K
McCann, L
Hackshaw, M
Crescenzo, R
Pandite, L
Choueiri, T
Affiliation
Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA.Issue Date
2013-08-22
Metadata
Show full item recordAbstract
Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy.Citation
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. 2013, 369 (8):722-31 N Engl J MedJournal
The New England Journal of MedicineDOI
10.1056/NEJMoa1303989PubMed ID
23964934Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1303989
Scopus Count
Collections
Related articles
- Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
- Authors: Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R
- Issue date: 2018 May 22
- Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
- Authors: Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H
- Issue date: 2010 Dec
- The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
- Authors: Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, Hong B, Song C, Ahn H
- Issue date: 2010 Oct
- Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.
- Authors: Amaro F, Pisoeiro C, Valente MJ, Bastos ML, Guedes de Pinho P, Carvalho M, Pinto J
- Issue date: 2022 Aug 31
- Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma.
- Authors: Annala M, Nappi L, Azad AA, Mo F, Fazli L, Chi KN, Wyatt AW
- Issue date: 2017 Feb